Kanada - inglise - Health Canada

pharmascience inc - desmopressin acetate (desmopressin acetate trihydrate) - tablet - 0.2mg - desmopressin acetate (desmopressin acetate trihydrate) 0.2mg - pituitary

Kanada - inglise - Health Canada

nu-pharm inc - desmopressin acetate - metered-dose pump - 0.1g - desmopressin acetate 0.1g - pituitary

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - desmopressin acetate trihydrate 0.1mg equivalent to desmopressin 0.0890 mg;   - tablet - 100 mcg - active: desmopressin acetate trihydrate 0.1mg equivalent to desmopressin 0.0890 mg   excipient: lactose monohydrate magnesium stearate maize starch povidone

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - desmopressin acetate trihydrate 0.2mg equivalent to desmopressin 0.178 mg;   - tablet - 200 mcg - active: desmopressin acetate trihydrate 0.2mg equivalent to desmopressin 0.178 mg   excipient: lactose monohydrate magnesium stearate maize starch povidone

Kanada - inglise - Health Canada

aa pharma inc - desmopressin acetate - spray, metered dose - 10mcg - desmopressin acetate 10mcg - pituitary

Kanada - inglise - Health Canada

meliapharm inc - desmopressin acetate trihydrate - tablet - 0.1mg - desmopressin acetate trihydrate 0.1mg - pituitary

Kanada - inglise - Health Canada

meliapharm inc - desmopressin acetate trihydrate - tablet - 0.2mg - desmopressin acetate trihydrate 0.2mg - pituitary

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - desmopressin acetate - spray - 10microgram/1dose

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

kvk-tech, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - central diabetes insipidus desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. primary nocturnal enuresis desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. desmopressin acetate is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min). desmopressin acetate is contraindicated in patients with hyponatremia or a history of hyponatremia.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - hemophilia a: desmopressin acetate injection 4 mcg/ml is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5%. desmopressin acetate will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. desmopressin acetate will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. desmopressin acetate is not indicated for the treatment of hemophilia a with factor viii coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia b, or in patients who have factor viii antibodies. in certain clinical situations, it may be justified to try desmopressin acetate in patients with factor viii levels between 2% to 5%; however, these patients should be carefully monitored. von willebrand’s disease (type i): desmopressin acetate injection